Merck KGaA

                   

Doctors debate Vytorin cancer risk at heart meeting

reutershealth.com
14-Nov-2008 14 related
        

NEW ORLEANS (Reuters) - Researchers attempted on Wednesday to calm concerns about the potential cancer risks of cholesterol fighters Vytorin and Zetia, while others urged caution in prescribing the drugs until larger trials...

add comment

HIV Vaccine Failure Still Brings Insights

medicinenet.com
14-Nov-2008 2 related
        

HealthDay Reporter THURSDAY, Nov. 13 (HealthDay News) -- The latest attempt to develop an "It's raised a whole new set of questions that are going to be really important to answer to get us to a successful vaccine," said Dr....

add comment
                   
genengnews.com: Genetic Engineering genengnews.com

Compugen Reports Third Quarter 2008 Financial Results

euroinvestor.co.uk
13-Nov-2008 17 related
        

Compugen Ltd. (NASDAQ:CGEN) today reported financial results for the third quarter ending September 30, 2008. Martin Gerstel, Compugen´s chairman, stated, "The field of peptide therapeutics is o.. - Read more

add comment
                   

Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months

pharmiweb.co.uk
13-Nov-2008 5 related
        

who received chemotherapy alone. 1 This effect was more pronounced in patients treated with Erbitux who developed early acne-like rash, resulting in median overall survival of 15 months.1 In the overall population of FLEXa, the...

add comment
                   

Big Pharma Eyes Biotech Deals, But Cautionsly (DJ)

pharmiweb.co.uk
13-Nov-2008
        

By Peter Loftus Of DOW JONES NEWSWIRES Large pharmaceutical companies flush with cash expect an acceleration in acquisitions of small and mid-sized drug companies, but executives say they're not going on reckless shopping...

add comment
genengnews.com: Genetic Engineering genengnews.com

HIV Vaccine Failure Still Brings Insights (HealthDay)

yahoo.com
13-Nov-2008 82 related
        

HealthDay - THURSDAY, Nov. 13 (HealthDay News) -- The latest attempt to develop an AIDS vaccine has failed, but researchers report that they've still gained insight into how to make the next one more effective.

add comment
                   

Micromet to Present Interim Data from Two Studies for T Cell Engaging BiTE Antibody Blinatumomab...

finanznachrichten.de
13-Nov-2008 5 related
        

BETHESDA, Md., Nov. 13 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that two...

add comment
                   

AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results (PR Newswire)

yahoo.com
13-Nov-2008 4 related
        

Thursday November 13, 7:30 am ET All amounts are in U.S. dollars QUEBEC CITY, Nov. 13 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrinology and...

add comment

T-cell-based HIV-1 vaccine found effective

upi.com
13-Nov-2008 2 related
        

BOSTON, Nov. 13 (UPI) -- A U.S.-led team of scientists says it's demonstrated for the first time the effectiveness of a T-cell-based human immunodeficiency virus vaccine in monkeys. Dr. Dan Barouch of the Beth Israel Deaconess...

add comment

Results of landmark study of HIV vaccine published in the Lancet

brightsurf.com
13-Nov-2008 10 related
        

Results from the Step study, a test-of-concept efficacy study of a Merck & Co., Inc. HIV vaccine candidate, were published online today in two papers in The Lancet. These analyses of the Step study are being conducted,...

add comment